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Summary  Diabetes  mellitus  has  reached  an  epidemic  level  worldwide.  Cardiovascular
diseases are  the  primary  cause  of  death  in  diabetic  patients,  not  only  because  of  coronary
artery disease  and  associated  hypertension  but  also  because  of  a  direct  adverse  effect  of  dia-
betes on  the  heart,  independent  of  other  potential  aetiological  factors.  However,  the  existence
of this  ‘diabetic  cardiomyopathy’  remains  controversial.  We  aimed  to  review  current  evidence
for the  existence  of  diabetic  cardiomyopathy,  focusing  particularly  on  the  clinical  setting.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  diabète  a  atteint  un  niveau  épidémique  sur  le  plan  mondial.  Les  pathologies  car-
diovasculaires  représentent  la  première  cause  de  décès  chez  les  patients  atteints  de  diabète
non seulement  du  fait  des  cardiopathies  ischémiques  et  de  l’hypertension  artérielle  associées
au diabète  mais  également  du  fait  d’un  effet  délétère  du  diabète  lui-même  sur  le  plan  car-
diaque indépendamment  de  tout  autre  facteur  étiologique  potentiel.  Cependant,  l’existence  de
cette « cardiomyopathie  diabétique  » reste  controversée.  Le  but  de  cette  revue  de  la  littérature
 de  lest de  discuter  des  preuves
principalement  au  champ  cliniqu
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Abbreviations: BMI, body mass index; CI, conﬁdence interval; CITP, 
CM, diabetic cardiomyopathy; LV, left ventricular; MMP, matrix metallo
ype I; STI, speckle tracking imaging; TDI, tissue Doppler imaging; TIMP, 
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carboxy-terminal telopeptide of collagen type I;
proteinase; PICP, carboxy-terminal propeptide of procollagen
tissue inhibitors of matrix metalloproteinase.
served.
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Background
A  tsunami  of  obesity  has  been  recently  described,  with
1.46  billion  overweight  adults  (BMI  ≥  25  kg/m2)  in  2008,
including  500  million  who  were  obese  (BMI  ≥  30  kg/m2) [1].
Consequently,  diabetes  mellitus  has  reached  an  epidemic
level  worldwide,  with  a  prevalence  of  4%  in  1995  and  an
anticipated  prevalence  of  5.4%  in  2025,  corresponding  to
300  million  adults  with  diabetes  worldwide  [2].  Cardiovas-
cular  diseases  represent  the  primary  cause  of  death  in  this
population  because  of  coronary  artery  disease  [3]  or  asso-
ciated  hypertension  but  also  because  of  a  direct  adverse
effect  of  diabetes  mellitus  on  the  heart,  called  DCM.  Dia-
betes  mellitus  is  a  complex  metabolic  disorder  that  includes
insulin  resistance  (in  type  2),  often  associated  with  hyper-
tension  and  obesity  [4].  All  those  conditions  are  associated
with  a  high  risk  of  coronary  artery  disease  but  may  also
exert  a  direct  negative  effect  on  the  myocardium.  Among
them,  the  speciﬁc  negative  effect  of  diabetes  mellitus  on
the  heart,  leading  to  DCM,  has  been  extensively  investigated
in  the  last  three  decades.  Controversies  exist  regarding  the
existence  of  a  speciﬁc  DCM,  as  this  concept  has  mainly
emerged  from  experimental  models  [5].  In  this  review,  we
aimed  to  discuss  the  current  evidence  for  the  existence  of
DCM,  focusing  particularly  on  the  clinical  setting.
Deﬁnition of diabetic cardiomyopathy
(DCM)
DCM  was  ﬁrst  described  40  years  ago,  based  on  post-mortem
observations  in  four  diabetic  patients  with  heart  failure  but
no  coronary  artery  disease  or  other  aetiological  conditions
explaining  heart  failure  [6].  The  authors  observed  LV  hyper-
trophy  associated  with  myocardial  ﬁbrosis  in  those  patients
and  introduced  for  the  ﬁrst  time  the  concept  of  DCM  [6].
Five  years  later,  Regan  et  al.  [7]  conﬁrmed  those  results  and
described  cases  of  heart  failure  in  familial  diabetes  without
coronary  artery  disease,  hypertension  or  obesity.  A  higher
myocardial  collagen  and  lipid  content  was  also  reported  in
those  cases  compared  with  control  subjects  [7].
Since  those  initial  studies,  DCM  has  been  deﬁned  as  the
existence  of  LV  dysfunction  in  diabetic  patients  without
coronary  artery  disease,  hypertension  or  other  potential
aetiological  condition.
Experimental evidence
Numerous  experimental  studies,  mainly  based  on  rodent
models,  have  demonstrated  a  direct  negative  effect  of  dia-
betes  mellitus  on  the  myocardium  [8,9]. Pathophysiological
mechanisms  include  metabolic  alterations  with  impaired
calcium  homeostasis,  alteration  of  substrate  utilization
(increase  in  lipid  use  and  decrease  in  glucose  oxidation),
lipotoxicity,  glucotoxicity  with  intervention  of  advanced  gly-
cation  end  products,  mitochondrial  dysfunction,  increase  in
oxidative  stress,  renin-angiotensin-aldosterone  system  acti-
vation  and  cardiac  dysautonomia.  All  these  mechanisms  lead
to  an  increase  in  myocardial  cellular  death  (necrosis  and
apoptosis)  and  to  myocardial  ﬁbrosis,  with  the  consequent
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Aigure 1. Physiopathology of diabetic cardiomyopathy (DCM). LV:
eft ventricular.
evelopment  of  myocardial  dysfunction  and  overt  heart
ailure  (Fig.  1)  [8,9].
pidemiological evidence
n  the  clinical  setting,  the  most  convincing  evidence  for  the
xistence  of  DCM  comes  from  large  epidemiological  studies.
wo  years  after  the  study  of  Rubler  et  al.  [6],  the  Framing-
am  Heart  Study  investigators  demonstrated  that  diabetes
ellitus  was  an  independent  risk  factor  for  heart  failure
10].  Risk  of  heart  failure  was  2.4-fold  and  5-fold  higher  in
iabetic  men  and  women,  respectively,  than  in  non-diabetic
ubjects.  The  increased  incidence  of  heart  failure  in  diabetic
atients  persisted  even  after  adjustment  for  age,  hyper-
ension,  obesity,  coronary  artery  disease  or  dyslipidaemia
10].
Diabetes  mellitus  as  an  independent  risk  factor  for  heart
ailure  has  been  conﬁrmed  in  numerous  epidemiological
tudies  [11—17]. In  a  prospective  study  including  2700
lderly  subjects  (mean  age  81  ±  9  years),  the  incidence
f  heart  failure  during  a  43-month  follow-up  was  1.3-fold
igher  in  diabetes  mellitus  than  in  euglycaemic  subjects
fter  adjustment  for  age,  hypertension,  coronary  artery
isease  and  sex  [11]. The  Cardiovascular  Health  Study,
ncluding  5888  subjects  aged  more  than  65  years  with  a  mean
elay  of  5.5  years  follow-up,  reported  an  incidence  rate  for
eart  failure  of  19.3/1000  person-years,  with  a  substantially
igher  incidence  (approximately  2-fold)  associated  with  dia-
etes  mellitus  [15]. In  a large  case-control  study,  Bertoni
t  al.  [12]  tested  the  hypothesis  that  diabetes  mellitus  was
ndependently  associated  with  idiopathic  cardiomyopathy.
fter  adjusting  for  age,  sex,  race  and  hypertension,  diabetes
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ellitus  was  signiﬁcantly  associated  with  idiopathic  car-
iomyopathy  (relative  odds  1.58,  95%  CI  1.55—1.62).  Those
esults  were  conﬁrmed  in  a  second  case-control  study  [13].
n  the  French  EPICAL  Study,  prevalence  of  diabetes  mellitus
mong  patients  with  non-ischaemic  advanced  heart  failure
as  19.7%  [17]. In  the  Reykjavik  Study,  Thrainsdottir  et  al.
16]  explored  the  associations  between  heart  failure  and
bnormal  glucose  regulation  (impaired  glucose  tolerance  or
mpaired  fasting  glucose)  or  type  2  diabetes  mellitus  in  a
opulation-based  cohort  of  19,381  participants.  The  odds
atio  was  2.8  (95%  CI  2.2—3.6)  for  the  association  between
ype  2  diabetes  mellitus  and  heart  failure  and  1.7  (95%
I  1.4—2.1)  for  the  association  between  abnormal  glucose
egulation  and  heart  failure.
Finally,  the  Strong  Heart  Study  recently  conﬁrmed  dia-
etes  mellitus  as  an  independent  risk  factor  of  heart
ailure  [14]. In  a  population-based  cohort  of  1204  sub-
ects,  the  authors  showed  a  1.5-fold  higher  risk  of  heart
ailure  in  patients  with  diabetes  mellitus  after  adjust-
ent  for  multiple  cofactors  (age,  sex,  obesity,  central  fat
istribution,  antihypertensive  medications,  atrial  ﬁbrilla-
ion,  urinary  albumin/creatinine  ratio,  plasma  cholesterol,
b1Ac,  smoking  habit,  alcohol  use,  educational  level  and
hysical  activity).  Interestingly,  for  the  ﬁrst  time,  intercur-
ent  myocardial  infarction  was  censored  in  this  analysis  [14].
oninvasive evidence for adverse effects
f diabetes mellitus on the heart (left
entricular structure, remodelling and
unction)
oninvasive evidence for structural
yocardial  abnormalities associated with
iabetes
yocardial  ﬁbrosis
yocardial  ﬁbrosis,  as  initially  described  by  Rubler  et  al.
6]  and  conﬁrmed  in  both  histological  studies  in  humans
7,18,19]  and  experimental  studies  [20], is  a  major  conse-
uence  of  the  adverse  effects  of  diabetes  mellitus  on  the
eart  [8].  Backscatter  is  an  ultrasound  tissue  characteri-
ation  technique  based  on  the  measurement  of  myocardial
issue  echoreﬂectivity,  which  is  related  to  myocardial  colla-
en  content  [21]. Di  Bello  et  al.  [22]  showed  an  increase
n  myocardial  echodensity  as  assessed  by  the  integrated
ackscatter  index  in  26  insulin-dependent  diabetic  nor-
otensive  patients  compared  with  17  age-  and  sex-matched
ontrol  subjects.  Fang  et  al.  [23]  conﬁrmed  these  results
sing  calibrated  integrated  backscatter  in  a  larger  study.
Biomarkers  of  collagen  synthesis  (PICP;  PINP,  amino-
erminal  propeptide  of  procollagen  type  I;  PIIICP,  carboxy-
erminal  propeptide  of  procollagen  type  III;  PIIINP,  amino-
erminal  propeptide  of  procollagen  type  III)  or  collagen
egradation  (CITP)  have  been  showed  to  be  of  clinical
nterest  in  detecting  myocardial  ﬁbrosis  [24]. In  addition,
arkers  of  extracellular  matrix  turnover  (such  as  MMP)
nd  their  inhibitors  (TIMP,  tissue  inhibitors  of  MMP)  might
lso  be  useful  [24]. However,  few  studies  have  used  these
iomarkers  in  diabetic  patients.  An  increase  in  CITP  was
[
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ecently  described  in  type  2  diabetic  patients  compared
ith  control  subjects  and  was  correlated  with  diastolic  func-
ion  (mitral  A  duration  minus  pulmonary  vein  atrial  reversal
elocity  duration)  [25]. MMP-7  has  also  been  shown  to  be
ssociated  with  diastolic  dysfunction  with  microvascular
omplications  (nephropathy)  [26]. Patients  with  diastolic
ysfunction  demonstrated  an  increase  in  MMP-9  and  a
ecrease  in  TIMP-1/MMP-9  [26]. Finally,  in  a  small  group
f  diabetic  patients,  correlation  was  found  between  PICP
nd  LV  systolic  variables  (fractional  shortening  and  midwall
ractional  shortening)  [27].
yocardial  steatosis
n  increase  in  myocardial  lipid  content  (myocardial  steato-
is)  has  been  demonstrated  in  diabetic  patients  using
H-magnetic  resonance  spectroscopy.  McGavock  et  al.  [28]
howed  an  increase  in  myocardial  triglyceride  content  in  glu-
ose  intolerant  patients  and  in  patients  with  type  2  diabetes
ellitus  compared  with  controls.  Myocardial  triglyceride
ontent  was  associated  with  diastolic  function  variables  (E/A
atio  and  E  wave  deceleration  time)  [29]. In  a  group  of  42
en  with  type  2  diabetes  mellitus,  patients  with  a  high
yocardial  triglyceride  content  (superior  to  the  median  of
he  population)  presented  a  decrease  in  systolic  strain  and
train  rate  whereas  LV  ejection  fraction  was  similar  in  the
wo  groups  [30].
hese structural abnormalities are associated
ith morphological and functional
bnormalities
oncentric  remodelling  and  left  ventricular
ypertrophy
oncentric  remodelling  is  deﬁned  as  an  increase  in  relative
all  thickness  ([2  ×  posterior  wall  thickness]/end-diastolic
iameter)  with  normal  LV  mass  index  values,  whereas  LV
ypertrophy  is  deﬁned  as  abnormal  LV  mass  index  values
31].  Concentric  remodelling  and  LV  hypertrophy,  known
o  be  of  adverse  prognostic  value  [32], are  the  most  fre-
uently  described  morphological  abnormalities  associated
ith  diabetes  mellitus  [33—37]. In  the  Framingham  Heart
tudy,  Galderisi  et  al.  [35]  showed  an  increase  in  LV  mass  and
all  thickness  independently  associated  with  diabetes  mel-
itus,  but  in  multivariable  analysis,  statistical  signiﬁcance
as  reached  only  in  women.  In  the  Cardiovascular  Health
tudy,  an  increase  in  LV  mass  was  independently  associ-
ted  with  diabetes  mellitus  even  after  adjustment  for  body
eight,  blood  pressure,  heart  rate  and  prevalent  coronary
r  cerebrovascular  disease  [36]. However,  in  contrast  to  pre-
ious  ﬁndings,  this  association  was  signiﬁcant  in  both  men
nd  women  [36]. The  Strong  Heart  Study  conﬁrmed  these
esults  in  a  large  cohort  of  American  Indians  (1810  par-
icipants  with  diabetes  mellitus  and  944  glucose-tolerant
ubjects)  [33]. In  this  population,  increases  in  wall  thick-
ess  and  LV  mass  were  associated  with  a  slight  decrease  in
V  fractional  shortening  and  midwall  fractional  shortening  in
iabetic  patients  compared  with  glucose-tolerant  subjects
33].  All  these  studies  described  concentric  remodelling  and
V  hypertrophy  associated  with  diabetes  mellitus,  indepen-
ent  of  other  confounding  factors  such  as  age,  obesity  (BMI)
nd  hypertension.  However,  more  recently,  the  NOMAS  Study
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described  diabetes  mellitus  as  an  independent  determinant
of  LV  mass  but  in  addition  to  central  obesity  as  assessed  by
waist  circumference  [34].
Impact  of  diabetes  on  left  ventricular  remodelling
The  impact  of  diabetes  mellitus  on  LV  remodelling  over  the
course  of  a  lifetime  has  been  demonstrated  more  recently.
Indeed,  the  Framingham  Heart  Study  investigators  showed,
in  a  ﬁrst  report,  an  increase  in  LV  mass  during  a  16-year
follow-up  [38]. Diabetic  subjects  (without  heart  failure
or  previous  myocardial  infarction)  experienced  a  steeper
increase  in  LV  mass  with  advancing  age  than  non-diabetic
subjects  [38]. In  a  second  report,  Cheng  et  al.  [39]  demon-
strated  an  increase  in  wall  thickness  with  advancing  age
associated  with  a  decrease  in  LV  diameter  and  a  concomi-
tant  increase  in  fractional  shortening.  This  study  pointed
out  the  inﬂuence  of  diabetes  mellitus,  in  addition  to  sex
and  hypertension,  on  LV  remodelling  over  life.  Indeed,  dia-
betes  mellitus  was  associated  with  a  greater  increase  in  wall
thickness  coupled  with  a  smaller  decrease  in  LV  diameter
[39].
Finally,  Markus  et  al.  [40]  also  reported  the  inﬂuence
of  diabetes  mellitus  on  LV  remodelling.  During  a  10-year
follow-up  in  a  population-based  cohort  of  1005  subjects,
the  authors  observed  a  greater  increase  in  LV  mass  in
patients  with  prevalent  diabetes  mellitus  associated  with
an  increase  in  LV  end-diastolic  diameter,  whereas  this  last
variable  remained  stable  over  time  in  euglycaemic  subjects
[40];  this  was  associated  with  a  decrease  in  LV  ejection  frac-
tion  in  prevalent  diabetic  subjects  whereas  an  increase  was
observed  in  euglycaemic  subjects  [40].
Functional  abnormalities
Longitudinal  systolic  impairment
Myocardial  strain  imaging,  such  as  TDI  and  STI,  is  use-
ful  for  detecting  ischaemia  [41]. These  techniques  also
facilitate  demonstration  of  subclinical  impairment  of  sys-
tolic  function  in  asymptomatic  diabetic  patients  without
overt  heart  disease  and  a  normal  standard  echocar-
diography  compared  with  controls  [23,42—50].  Whereas
conventional  methods  such  as  LV  ejection  fraction  and
fractional  shortening  were  insensitive  in  terms  of  detect-
ing  early  preclinical  abnormalities,  longitudinal  dysfunction
was  demonstrated  in  many  studies  using  both  TDI
[23,42,44,45,48—50]  and  STI  [43,46,47]. For  some  authors,
longitudinal  strain  decrease  was  correlated  with  dia-
betes  imbalance  (glycated  haemoglobin)  or  microvascular
complications  (microalbuminuria)  [50]. However,  longitu-
dinal  alteration  is  independently  associated  with  diabetes
mellitus,  regardless  of  LV  hypertrophy  [23]  or  other  conven-
tional  risk  factors  [43].
Radial  systolic  impairment
Radial  systolic  function  has  been  investigated  less  fre-
quently  in  this  population.  Indeed,  only  a  few  studies
have  assessed  radial  function,  with  conﬂicting  results
[43,44,46,47,50].  The  initial  studies  suggested  that  radial
function  was  increased  [44,50]  or  preserved  [47]  to  com-
pensate  for  longitudinal  function  alteration.  However,  most
of  these  studies  were  based  on  TDI  and  its  derived  velo-
city  and  strain  rate  measurements  that  depend  on  Doppler
angle  [44,50].  The  TDI  measurements  are  limited  to  the
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egments  in  which  motion  and  deformation  are  aligned
ith  the  ultrasound  beam  and  hence  do  not  provide  an
ptimal  evaluation  of  radial  function.  STI  is  an  angle-
ndependent  method  and  allows  a  more  robust  and  extensive
valuation  of  radial  function  (Fig.  2)  [51]. Among  reports
ased  on  STI,  the  study  by  Ng  et  al.  [47]  described  pre-
erved  radial  function  compared  with  euglycemic  subjects
radial  strain  40.6  ±  11.1  vs.  42.7  ±  12.1%,  respectively;  P
ot  signiﬁcant).  However,  this  study  was  based  on  a  highly
elected  population  that  included  uncomplicated  patients
nd  only  men  with  a  short  duration  of  diabetes  mellitus
4  years)  and  a  strictly  controlled  haemoglobinA1c  concen-
ration  (6.4  ±  0.7%).  Conversely,  our  group  demonstrated  in
 population  of  114  diabetic  subjects,  a  decrease  in  both
adial  strain  (50  ±  16  vs.  56  ±  12%;  P  =  0.003)  and  longitudi-
al  strain  (—19  ±  3  vs.—22  ±  2%;  P  <  0.001)  compared  with
8  age-matched  controls  without  cardiovascular  risk  factors
43]. In  multivariable  analysis,  diabetes  mellitus  was  inde-
endently  associated  with  longitudinal  strain  (in  addition  to
ex)  and  radial  strain.  These  ﬁndings  remained  stable  in  a
ubgroup  analysis  of  42  strictly  age-,  sex-  and  BMI-paired
atients  and  controls  [43].
ontractile  reserve
hether  diabetes  mellitus  is  also  responsible  for  a  decrease
n  contractile  reserve  in  asymptomatic  patients  without
vert  heart  disease  is  a controversial  issue  [50,52—54].
alderisi  et  al.  [53]  demonstrated  an  impaired  inotropic
esponse  to  dobutamine  in  24  diabetic  patients  com-
ared  with  16  controls.  With  dobutamine,  myocardial  strain
ssessed  by  TDI  increased  by  36.4  ±  15.9%  in  diabetic
atients  vs.  57.1  ±  22.1%  in  controls  (P  =  0.0001).  Ha  et  al.
54]  showed  impairment  of  longitudinal  function  reserve  (as
ssessed  by  mitral  annular  systolic  velocity)  during  exercise.
owever,  Fang  et  al.  [52]  reported  a  normal  response  to
obutamine  stress,  suggesting  that  ischaemia  due  to  small
essel  disease  might  not  be  important  in  early  diabetic  heart
uscle  disease.
iastolic  dysfunction
iastolic  dysfunction  has  been  extensively  studied  in
iabetic  patients  without  overt  heart  disease  [55—63].
revalence  of  diastolic  dysfunction  is  high  in  diabetic
atients,  ranging  from  21%  to  75%  [55—63]. However,  hetero-
eneity  of  populations  enrolled  and  methodological  issues
egarding  the  assessment  of  diastolic  function  account  for
he  highly  variable  prevalence  reported  in  these  studies
55—63].  Indeed,  most  of  the  reports  were  based  on  one
ingle  abnormal  variable  using  mitral  inﬂow  pattern  [63],
ts  variation  with  the  Valsalva  manoeuvre  [62]  or  combined
ndices  derived  from  mitral  inﬂow  pattern  and  pulmonary
enous  ﬂow  [60]. More  recently,  some  authors  analysed
DI  diastolic  velocities  and  derived  indices  [55—58]  but
nly  two  studies  were  based  on  a  more  complex  diagnos-
ic  algorithm  and  a  comprehensive  evaluation  of  diastolic
unction  [59,61].  However,  in  the  study  of  Poulsen  et  al.
61], including  a  population  of  patients  with  type  2  dia-
etes  mellitus,  9%  presented  a  LV  ejection  fraction  less
r  equal  than  50%  and  30%  of  patients  presented  perfu-
ion  abnormalities  assessed  by  scintigraphy.  Kiencke  et  al.
59]  included  100  patients  with  type  2  diabetes  mellitus
nd  explored  diastolic  function  using  a  comprehensive  algo-
ithm  close  to  the  current  recommendations;  they  found  a
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Figure 2. Example of myocardial strain assessment by speckle tracking imaging (STI): radial strain (upper panel); longitudinal strain (lower
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revalence  of  diastolic  dysfunction  of  48%.  Recently,  in  a
tudy  strictly  based  on  the  current  European  Association
f  Echocardiography/American  Society  of  Echocardiogra-
hy  recommendations,  our  group  reported  a  prevalence  of
iastolic  dysfunction  of  47%  (33%  grade  I and  14%  grade
I).
d
i
p
tDiastolic  dysfunction  has  been  traditionally  considered
s  the  ﬁrst  marker  of  DCM  [56,58,60]. However,  whether
iastolic  dysfunction  reported  in  diabetic  patients  is  an
ndependent  adverse  effect  of  diabetes  mellitus  has  been
oorly  investigated.  Indeed,  the  association  between  poten-
ial  confounding  factors  (such  as  hypertension,  obesity,  age
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and  sex)  and  diastolic  function  was  not  taken  into  account
in  many  studies.  We  recently  demonstrated  that  in  con-
trast  to  systolic  impairment  in  diabetic  patients,  diastolic
variables  are  mainly  associated  with  other  factors  (inclu-
ding  age,  rate  pressure  product,  history  of  hypertension  and
BMI)  and  that  some  of  the  most  frequently  used  diastolic
variables  (E/A  ratio,  é  velocity)  are  not  independently  asso-
ciated  with  diabetes  mellitus  [64]. In  addition,  standard  LV
systolic  variables  are  mostly  insensitive  to  detecting  systolic
impairment.  When  using  myocardial  systolic  strain,  we  found
that  28%  of  patients  presented  longitudinal  dysfunction  with
normal  diastolic  function  [64].
Nevertheless,  diastolic  variables  are  related  to  prognosis
in  diabetic  patients  without  patent  heart  disease  [57—59]. In
a  ﬁrst  retrospective  study,  including  486  diabetic  patients,
From  et  al.  [57]  demonstrated  that  the  E/é  ratio  was  asso-
ciated  with  an  increase  in  global  mortality  after  adjustment
for  age,  sex,  coronary  artery  disease,  hypertension,  LV  ejec-
tion  fraction,  left  atrial  volume  and  delay  between  diabetes
diagnosis  and  echocardiography.  In  a  second  retrospective
study,  including  1760  diabetic  patients,  the  same  authors
demonstrated  that  an  E/é  ratio  more  than  15  was  associ-
ated  with  a  cumulative  probability  of  development  of  heart
failure  at  5  years  of  36.9%  compared  with  16.8%  for  patients
with  an  E/é  ratio  less  or  equal  than  15  (P  =  0.001)  and,  with  a
higher  global  mortality  (30.8%  vs.  12.1%  at  5  years;  P  <  0.001)
[58]. Kiencke  et  al.  [59]  conﬁrmed  that  patients  with  dia-
stolic  dysfunction  had  a  lower  overall  event-free  survival
rate  than  patients  without  diastolic  dysfunction  (54  vs.  87%;
P  =  0.001).
Microvascular  alteration
Alteration  of  microvessels  associated  with  endothelial  dys-
function  has  been  described  in  both  experimental  models  of
diabetes  [65]  and  humans  [66]. Those  abnormalities  result
in  a  decrease  in  myocardial  blood  ﬂow  reserve  that  has  been
described  using  myocardial  contrast  echocardiography  (with
dipyridamole  and  exercise)  [67], technetium  99  m  sestamibi
scintigraphy  (with  dipyridamole)  [68]  or  positron  emission
tomography  (with  dipyridamole  or  cold  pressor  test)  [69,70].
However,  the  association  between  perfusion  reserve  alte-
ration  and  myocardial  dysfunction  remains  unclear.  Indeed,
Moir  et  al.  [67]  found  no  association  between  systolic  strain
alteration  and  perfusion.
Therapeutic perspectives
At  the  stage  of  heart  failure,  treatment  of  DCM  is  currently
based  on  common  heart  failure  guidelines  [71]. However,
the  main  challenge  in  this  pathology  is  to  develop  pre-
ventive  therapeutic  options  in  order  to  avoid  or  delay  the
progression  of  early  myocardial  dysfunction  associated  with
diabetes  mellitus  to  overt  heart  failure.  Indeed,  modern
imaging  techniques  allow  the  detection  of  adverse  effects  of
diabetes  mellitus  on  the  myocardium  at  a  very  early  precli-
nical  stage  but  the  prognostic  value  of  those  alterations
needs  to  be  deﬁned  in  order  to  develop  a  preventive  strat-
egy  for  patients  at  high  risk.  To  date,  because  of  the
paucity  of  the  data,  no  preventive  therapy  is  recommended
at  the  preclinical  stage  of  DCM.  Based  on  pathophysio-
logical  mechanisms,  renin-angiotensin-aldosterone  system223
ntagonists  [72,73]  or  antioxidative  therapy  [74—76]  might
e  of  interest.
onclusions
n  summary,  there  is  much  evidence  in  favour  of  the  exist-
nce  of  DCM:
post-mortem  and  histological  studies  introduced  the
concept  of  DCM;
epidemiological  studies  demonstrated  that  diabetes  is  an
independent  risk  factor  for  heart  failure;
experimental  studies  explored  the  pathophysiology  and
demonstrated  an  adverse  effect  of  diabetes  on  the  heart
in  animal  models;
alteration  of  myocardial  content  (myocardial  ﬁbrosis  and
steatosis)  was  demonstrated  with  noninvasive  techniques;
and  ﬁnally,  noninvasive  imaging  (especially  echocardiog-
raphy)  demonstrated  a  preclinical  form  of  diabetic  heart
disease  with  subtle  alterations  in  LV  morphology,  remo-
delling  and  systolic  and  diastolic  function.
However,  whether  the  preclinical  form  of  DCM  is  of  prog-
ostic  signiﬁcance  and  leads  to  overt  heart  failure  with
ncreased  mortality  remains  to  be  investigated.  In  addition,
revention  therapies  that  could  avoid  the  evolution  to  overt
eart  failure  need  to  be  deﬁned.
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